Anti-C5aR antibodies and uses thereof

Details Anti-C5aR antibodies and uses thereof Anti-C5aR antibodies and uses thereof

2003-01-24

2011-12-06

Gambel, Phillip (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S130100, C424S133100, C424S141100, C424S143100, C424S152100, C424S172100, C424S178100, C424S183100, C424S009100, C435S007100, C435S334000, C530S387100, C530S387300, C530S388100, C530S388200, C530S388220, C530S391300, C530S391700, C536S023100, C536S023500, C536S023530

Reexamination Certificate

active

08071096

ABSTRACT:
The present invention relates to antibodies which bind to C5aR and which are useful in diagnostic and therapeutic methods. The antibodies of the present invention are reactive with an extracellular loop of C5aR other than the N-terminal domain and are capable of substantially reducing or inhibiting the binding of C5ato C5aR and functional consequences of neutrophil chemoattractant receptor activation.

REFERENCES:
patent: 5480974 (1996-01-01), Morgan et al.
patent: 5861272 (1999-01-01), Li et al.
patent: 0 377 489 (1990-07-01), None
patent: 08109200 (1996-04-01), None
patent: WO 95/00164 (1995-01-01), None
patent: WO 96/39511 (1996-12-01), None
patent: WO 98/33908 (1998-07-01), None
patent: WO 02/38767 (2002-05-01), None
Rudikoff, et al. Proc Natl Acad Sci USA [1982] 79:1979-1983.
MacCallum, RM et al. J. Mol. Biol. [1996] 262:732-745.
Casset, F et al. Biochem. Biophys. Res. Comm. [2003] 307:198-205.
Wu, H et al. J. Mol. Biol. [1999] 294:151-162.
FitzGerald, DJP. Meth. Enzymol [1987] 151:139-145.
Colman, Research in Immunology 145: 33-36, 1994.
Kussie et al., J. Immunol. 152: 146-152, 1994.
Chen et al., EMBO J., 14: 2784-2794, 1995.
Crass et al., J. Biol. Chem 274: 8367-8370, 1999.
Pease et al. (Eur. J. Immunol 24: 211-215, 1994.
Elsner, et al., “C3a activates the respiratory burst in human polymorphonuclear neutrophilic leukocytes via pertussis toxin-sensitive g-proteins”, Blood, (1994), vol. 83, No. 11, pp. 33224-33331.
Farkas et al., “C5a receptor expression by TGW neuroblastoma cells”, NeuroReport (1999), vol. 10, No. 14, pp. 3021-3025.
Fayyazi et al., “The C5a receptor is expressed in normal renal proximal tubular but not in normal pulmonary or hepatic epithelial cells”, Immunology, (2000), vol. 99, No. 1, pp. 38-45.
Jagels, et al., “Proteolytic inactivation of the leukocyte C5a receptor by proteinases derived fromPorphyromonas gingivalis”, Infection and Immunity, (1996), vol. 64, No. 6, pp. 1984-1991.
Oppermann, et al., “Probing the human receptor for C5a anaphylatoxin with site-directed antibodies”, The Journal of Immunology, (1993) vol. 151, No. 7, pp. 3785-3794.
Schlaf, et al., “Differential expression of the C5a receptor on the main cell types of rat liver as demonstrated with a novel monoclonal antibody and by C5a anaphylatoxin-induced Ca2+release”, Laboratory Investigation, (1999) vol. 79, No. 10, pp. 1287-1297.
Sayah, et al., “Expression of cytokines by human astrocytomas following stimulation by C3a anaphylatorxins: specific increase in interleukin-6 mRNA expression”, Journal of Neurochemistry (1999), col. 72, No. 6, pp. 2426-2436.
Watanabe, et al., “Analysis of C5a receptor by monoclonal antibody”, Journal of Immunological Methods, (1995), vol. 185, No. 1, pp. 19-29.
Charlton R. et al. “The Expression of C5A Receptor (C5AR) (CD88) Is Associated with the Progression of Inflammation in Human Disease”. Journal of Pathology, Chichester, Sussex, GB, vol. 187, No. suppl. 1999, p. 36A.
Monk, et al., Mutation of Glutamate 199 of the Human C5a Receptor Defines a Binding Site for Ligand Distinct from the Receptor N Terminus, The American Society for Biochemistry and Molecular Biology, Inc., vol. 270, No. 28, Issue of Jul. 14, pp. 16625-16629, 1995.
Cain et al., Mapping the Ligand-Binding Site on the C5a Receptor: Arginine74 of C5a Contacts Aspartate282 of the C5a Receptor. Biochemistry 2001;40:14047-52.
Cain et al., Modulation of ligand selectivity by mutation of the first extracellular loop of the human C5a receptor. Biochem. Pharm. 2001;61:1571-9.
Crass et al., Receptor Activation by Human C5a des Arg74 but Not Intact C5a Is Dependent on an Interaction between Glu199 of the Receptor and Lys68 of the Ligand. Biochemistry 1999;38:9712-17.
Demartino et al., Arginine 206 of the C5a Receptor Is Critical for Ligand Recognition and Receptor Activation by C-terminal Hexapeptide Analogs. J. Biol. Chem. 1995;270(27):15966-9.
Gerber et al., An Activation Switch in the Ligand Binding Pocket of the C5a Receptor. J. Biol. Chem. 2001;276:3394-3400.
Lee et al., Human C5aR knock-in mice facilitate the production and assessment of anti-inflammatory monoclonal antibodies. Nature Biotechnology 2006;24(10):1279-84.
Lee et al., 2006, “Human C5aR knock-in mice facilitate the production and assessment of anti-inflammatory monoclonal antibodies,” Nature Biotechnology, 24(10):1279-1284.
Extended European Search Report for European Application No. 10009060.4, dated Jul. 29, 2011.
Raffetseder, et al. (1996) “Site-Directed Mutagenesis of Conserved Charged Residues in the Helical Region of the Human C5a Receptor. Arg2O6 Determines High-Affinity Binding Sites of C5a Receptor” Eur. J. Biochem. 235 (1-2):82-90.
Rothermel, et al. (2000) “Analysis of the Tissue Distribution of the Rat C5a Receptor and Inhibition of C5a-Mediated Effects through the Use of Two MoAbs” Scand. J. Immunol. 52(4):401-410.

Affiliated with

Also associated with

Rating

Anti-C5aR antibodies and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-C5aR antibodies and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-C5aR antibodies and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4268941